These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2174522)

  • 1. Cholecystokinin antagonists proglumide, lorglumide and benzotript, but not L-364,718, interact with brain opioid binding sites.
    Gaudreau P; Lavigne GJ; Quirion R
    Neuropeptides; 1990 May; 16(1):51-5. PubMed ID: 2174522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
    van der Bent A; Blommaert AG; Melman CT; IJzerman AP; van Wijngaarden I; Soudijn W
    J Med Chem; 1992 Mar; 35(6):1042-9. PubMed ID: 1552499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
    Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment.
    Kellstein DE; Mayer DJ
    Brain Res; 1990 May; 516(2):263-70. PubMed ID: 2364292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do antagonists of pancreatic cholecystokinin receptors interact with central nervous system cholecystokinin receptors?
    Vigna SR; Szecòwka J; Williams JA
    Brain Res; 1985 Sep; 343(2):394-7. PubMed ID: 2996701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors.
    Wang XJ; Han JS
    J Neurochem; 1990 Oct; 55(4):1379-82. PubMed ID: 2168937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal co-administration of cholecystokinin antagonists with morphine prevents the development of opioid tolerance.
    Kellstein DE; Mayer DJ
    Pain; 1991 Nov; 47(2):221-229. PubMed ID: 1762818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proglumide exhibits delta opioid agonist properties.
    Rezvani A; Stokes KB; Rhoads DL; Way EL
    Alcohol Drug Res; 1987; 7(3):135-46. PubMed ID: 3030338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells.
    Staley J; Jensen RT; Moody TW
    Peptides; 1990; 11(5):1033-6. PubMed ID: 2178246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats].
    Wang SX
    Zhongguo Yao Li Xue Bao; 1993 Sep; 14(5):443-6. PubMed ID: 8010038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.
    D'Amato M; Stamford IF; Bennett A
    Br J Pharmacol; 1991 Feb; 102(2):391-5. PubMed ID: 2015421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
    Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor.
    Yule DI; Williams JA
    Peptides; 1994; 15(6):1045-51. PubMed ID: 7527529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors.
    Sharif NA; Hughes J
    Peptides; 1989; 10(3):499-522. PubMed ID: 2550910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
    De Souza EB; Schmidt WK; Kuhar MJ
    J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin octapeptide antagonized opioid analgesia mediated by mu- and kappa- but not delta-receptors in the spinal cord of the rat.
    Wang XJ; Wang XH; Han JS
    Brain Res; 1990 Jul; 523(1):5-10. PubMed ID: 1976419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists.
    Hahne WF; Jensen RT; Lemp GF; Gardner JD
    Proc Natl Acad Sci U S A; 1981 Oct; 78(10):6304-8. PubMed ID: 6171817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cholecystokinin octapeptide (CCK-8) antagonized analgesia mediated by mu and kappa opioid receptors].
    Wang XH; Wang XJ; Han JS
    Sheng Li Xue Bao; 1990 Jun; 42(3):219-25. PubMed ID: 1982023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of receptors for gastrin and CCK on gastric smooth muscle cells.
    Menozzi D; Gardner JD; Jensen RT; Maton PN
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G73-9. PubMed ID: 2473654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.